Company Of The Day: Pfizer

+3.09%
Upside
27.75
Market
28.61
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion.

Why?

Relevant Articles
  1. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  2. Should You Pick Pfizer Stock At $30?
  3. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
  4. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  5. Is Pfizer Stock Undervalued At $40?
  6. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisitions to bolster revenue as vaccine sales peak off, with some of its top-selling drugs also set to go off patent.

So What?

We think Pfizer stock is undervalued. We value PFE at $63 per share, about 25% ahead of the current market price.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns May 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 1% -16% 52%
 S&P 500 Return -5% -17% 76%
 Trefis Multi-Strategy Portfolio -9% -25% 196%

[1] Month-to-date and year-to-date as of 5/12/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates